U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 77

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated June 25, 2024,	4. Expiration Date: May 31, 2026
1. Prime Healthcare Services - Kansas City, LLC d/b/a St. Joseph Medical Center 2. 1000 Carondelet Dr. Kansas City, MO 64114	3. License No.: 24-02704-01 is amended in its entirety to read as follows:	5. Docket No.: 030-02310 Reference No.:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. For any use permitted by 10 CFR 35.300.
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged kits	D. 3 millicuries total	D. For use in in-vitro studies.

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 24-02704-01	Docket or Reference No.: 030-02310
	Amendment No. 77	

CONDITIONS

10. Licensed material shall be used or stored only at the licensee's facilities located at 1000 Carondelet Dr., Kansas City, Missouri, 64114.

11. The Radiation Safety Officer (RSO) for this license is James R. Bergh, M.D.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User	Material and Use
Andy Lee Anderson, M.D.	10 CFR 35.100,10 CFR 35.200 (excluding generators),10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)
James R. Bergh, M.D.	10 CFR 31.11,10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
David J. Burkart, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Mark J. Clifft, M.D.	10 CFR 35.100,10 CFR 35.200 (excluding generators),10 CFR 35.300
Jeffrey A. Hicklin, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Kenneth L. Koontz, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Francisco J. Lammoglia, M.D.	10 CFR 35.100,10 CFR 35.200
Terry S. Lee, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Richard D. Miller, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Patrick M. O'Toole, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Milton R. Wolf, M.D.	10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 24-02704-01	Docket or Reference No.: 030-02310
	Amendment No. 77	

Authorized User	Material and Use
John S. Yungmeyer, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit in 10 CFR 30.35(d) for which decommissioning financial assurance is required.

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

A. Application dated November 12, 2015 (ML15323A045)
B. Letter dated December 22, 2015 (ML16123A194)
C. Letter dated March 2, 2016 (ML16082A518)
D. Letter dated April 22, 2016 (ML16123A197)
E. Letter dated January 16, 2017 (ML17031A412)
F. Letter dated August 21, 2017 (ML17269A188)

MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 24-02704-01	Docket or Reference No.: 030-02310
	Amendment No. 77	

G. Letter dated October 16, 2019 (ML19301D380)
H. Letter dated November 12, 2019 (ML19330D879)
I. Letter dated December 8, 2020 (ML21062A160)
J. Letter dated April 12, 2021 (ML21105A410)

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Bryan A. Parker Digitally signed by Bryan A. Parker Date: 2024.08.28 13:41:59 -04'00'

Date: August 28, 2024

By: _____

Bryan A. Parker
Region III